The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects
Open accessAbstract
Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy transfer α particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high-grade gliomas and either cutaneous primaries or cerebral metastases of melanoma, most recently, head and neck and liver cancer. Neutron sources for BNCT currently are limited to nuclear reactors and these are available in the United States, Japan, several European countries, and Argentina. Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT. Boron Delivery Agents: Two boron drugs have been used clinically, sodium borocaptate (Na2B12H11SH) and a dihydroxyboryl derivative of phenylalanine called boronophenylalanine. The major challenge in the development of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations (∼20 μg/g tumor) sufficient to deliver therapeutic doses of radiation to the tumor with minimal normal tissue toxicity. Over the past 20 years, other classes of boron-containing compounds have been designed and synthesized that include boron-containing amino acids, biochemical precursors of nucleic acids, DNA-binding molecules, and porphyrin derivatives. High molecular weight delivery agents include monoclonal antibodies and their fragments, which can recognize a tumor-associated epitope, such as epidermal growth factor, and liposomes. However, it is unlikely that any single agent will target all or even most of the tumor cells, and most likely, combinations of agents will be required and their delivery will have to be optimized. Clinical Trials: Current or recently completed clinical trials have been carried out in Japan, Europe, and the United States. The vast majority of patients have had high-grade gliomas. Treatment has consisted first of “debulking” surgery to remove as much of the tumor as possible, followed by BNCT at varying times after surgery. Sodium borocaptate and boronophenylalanine administered i.v. have been used as the boron delivery agents. The best survival data from these studies are at least comparable with those obtained by current standard therapy for glioblastoma multiforme, and the safety of the procedure has been established. Conclusions: Critical issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquantitative estimates of tumor boron content before treatment, improvements in clinical implementation of BNCT, and a need for randomized clinical trials with an unequivocal demonstration of therapeutic efficacy. If these issues are adequately addressed, then BNCT could move forward as a treatment modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Curran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
The Chemistry of Neutron Capture Therapy
Soloway, A. H., Tjarks, W., Barnum, B. A., Rong, F.-G., Barth, R. F., Codogni, I. M., & Wilson, J. G. (1998) · Chemical Reviews · doi:10.1021/cr941195u · Cited by 1,143
Self-citationThe Role of Chemistry in the Development of Boron Neutron Capture Therapy of Cancer
Hawthorne, M. F. (1993) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199309501 · Cited by 865
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Hepatic Resection Versus Transplantation for Hepatocellular Carcinoma
IWATSUKI, S., STARZL, T. E., SHEAHAN, D. G., YOKOYAMA, I., DEMETRIS, A. J., TODO, S., TZAKIS, A. G., VAN THIEL, D. H., CARR, B., SELBY, R., et al. (1991) · Annals of Surgery · doi:10.1097/00000658-199109000-00005 · Cited by 669
Ringe, B., Pichlmayr, R., Wittekind, C., & Tusch, G. (1991) · World Journal of Surgery · doi:10.1007/bf01659064 · Cited by 565
Targeting the epidermal growth factor receptor for cancer therapy.
Mendelsohn, J. M. (2002) · PubMed · Cited by 414
Flickinger, J. C., Kondziolka, D., Lunsford, L. D., Kassam, A., Phuong, L. K., Liscak, R., & Pollock, B. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00513-1 · Cited by 382
Cited by
Targeting nanoparticles to cancer
Wang, M., & Thanou, M. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.03.005 · Cited by 931
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Barth, R. F., H Vicente, M., Harling, O. K., Kiger, W., Riley, K. J., Binns, P. J., Wagner, F. M., Suzuki, M., Aihara, T., Kato, I., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-146 · Cited by 531
Self-citationDendrimers in Oncology: An Expanding Horizon
Tekade, R. K., Kumar, P. V., & Jain, N. K. (2009) · Chemical Reviews · doi:10.1021/cr068212n · Cited by 466
Therapeutic Potential of Boron-Containing Compounds
Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.71 · Cited by 373
Metadata
- Authors
- Barth, R. F., Coderre, J. A., Vicente, M. G. H., & Blue, T. E.
- Venue
- Clinical Cancer Research
- Published
- 2005-06-01
- Volume
- 11
- Issue
- 11
- Pages
- 3987-4002
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2145030327
- Cited by
- 1,046
- References
- 44
- FWCI
- 26.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-05-0035
- The paper
- Barth, R. F., Coderre, J. A., Vicente, M. G. H., & Blue, T. E. (2005). Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-05-0035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.